n | Univariate analysis | Multivariate analysis# | |||
OR (95% CI) | p-value | OR (95% CI) | p-value | ||
Age years | 239 | 0.99 (0.96–1.01) | 0.309 | ||
Male sex | 239 | 5.28 (1.51–18.43) | 0.009 | 4.63 (1.27–16.97) | 0.021 |
Body mass index kg·m−2 | 238 | 1.03 (0.98–1.08) | 0.285 | ||
Systolic BP mmHg | 237 | 0.99 (0.97–1.00) | 0.039 | 0.98 (0.96–1.00) | 0.010 |
Diastolic BP mmHg | 237 | 0.99 (0.96–1.01) | 0.218 | ||
Heart rate beats·min−1 | 238 | 1.01 (0.99–1.03) | 0.307 | ||
Atrial fibrillation | 238 | 0.81 (0.45–1.46) | 0.483 | ||
LVEF % | 239 | 0.98 (0.95–1.01) | 0.163 | ||
Plasma BNP pg·mL−1 | 177 | 1.00 (1.00–1.00) | 0.512 | ||
QRS duration ms | 237 | 1.00 (0.99–1.00) | 0.368 | ||
Serum creatinine mg·dL−1 | 229 | 0.88 (0.56–1.39) | 0.591 | ||
Haemoglobin g·dL−1 | 188 | 1.22 (1.02; 1.46) | 0.026 | 1.20 (0.99; 1.46) | 0.062 |
Non-use of antiarrhythmics | 239 | 4.16 (1.65–10.51) | 0.003 | 4.43 (1.68–11.65) | 0.003 |
β-blocker | 239 | 1.15 (0.47–2.79) | 0.764 | ||
Cardiac glycoside | 239 | 0.78 (0.42–1.47) | 0.445 | ||
Apnoea–hypopnoea index/h | 239 | 0.99 (0.97–1.01) | 0.193 | ||
CSR ≥20% | 238 | 2.09 (1.19–3.69) | 0.011 | 2.38 (1.28–4.45) | 0.006 |
Time with oxygen saturation <90%, % | 239 | 0.99 (0.98–1.00) | 0.158 |
Significant p-values (p<0.05) are marked in bold. LVEF: left ventricular ejection fraction; BNP: B-type natriuretic peptide; BP: blood pressure; CSR: Cheyne–Stokes respiration. #Adjusted for all independent variables with p<0.1 in the univariate models (sex, systolic blood pressure, antiarrhythmic use and CSR).